אודות פרק זה
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, led a case-based presentation and panel discussion featuring Susan O’Brien, Farrukh Awan, and Gilles Salles on optimizing chronic lymphocytic leukemia management in a changing landscape.
This educational activity is independently supported by Eli Lilly and Company. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.
אנגלית
ארצות הברית
תעתיק 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
פרקים אחרים בפודקאסט הזה
During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US.
Hosted on Acast. See acast.com/privacy for more information.
During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching Hospital, Leeds, UK. We asked, What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in chronic lympho…
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?
This educational resour…
Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?&n…
During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating zanubrutinib in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic ly…
הצהרה: הפודקאסט והגרפיקה המוטבעים בדף זה הם מ-Scientific Education Support, שהוא רכושו של בעליו ואינו קשור או מאושר על ידי Listen Notes, Inc.
